Will UnitedHealth Stock Recover?
Shares of embattled health insurance giant UnitedHealth (NYSE:UNH) plummeted by…
Buy
69
CBSC Quote, Financials, Valuation and Earnings
Last price:
$0.05
Seasonality move
:
25.38%
Day range:
$0.05 - $0.05
52-week range:
$0.02 - $0.10
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
202.72x
P/B ratio:
--
Volume:
--
Avg. volume:
21.2K
1-year change:
-11.64%
Market cap:
$8.7M
Revenue:
$41.4K
EPS (TTM):
-$0.01
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Cardiac Biotech Solutions, Inc. has -- downside to fair value with a price target of -- per share.
CBSC vs. S&P 500
-
Over the past 5 trading days, Cardiac Biotech Solutions, Inc. has overperformed the S&P 500 by 60.81% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Cardiac Biotech Solutions, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Cardiac Biotech Solutions, Inc. revenues have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Cardiac Biotech Solutions, Inc. reported revenues of $11.2K.
Earnings Growth
-
Cardiac Biotech Solutions, Inc. earnings have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Cardiac Biotech Solutions, Inc. reported earnings per share of -$0.00.
Enterprise value:
8.9M
EV / Invested capital:
--
Price / LTM sales:
202.72x
EV / EBIT:
--
EV / Revenue:
214.67x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-8.44x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$60.7K
Return On Assets:
-543.36%
Net Income Margin (TTM):
-2347.26%
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
-3289.42%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $82.4K | $135.1K | $41.4K | $10.4K | $6.9K | |
| Gross Profit | -$468.6K | -- | -- | -- | -- | |
| Operating Income | -$2.6M | -$1.6M | -$1.3M | -$331.5K | -$285.7K | |
| EBITDA | -$2.6M | -$1.6M | -$1.3M | -$331.5K | -$285.7K | |
| Diluted EPS | -$0.03 | -$0.01 | -$0.01 | -$0.00 | -$0.00 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $311.2K | $654K | $179.8K | $175.4K | $92.4K | |
| Total Assets | $311.8K | $654K | $304.8K | $300.4K | $167.4K | |
| Current Liabilities | $496.6K | $164.8K | $681.7K | $825.8K | $2M | |
| Total Liabilities | $501.7K | $164.8K | $681.7K | $943.2K | $2.1M | |
| Total Equity | -$189.9K | $489.1K | -$376.9K | -$642.8K | -$2M | |
| Total Debt | $5.1K | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $12.5M | -$860.8K | -$1.1M | -$123.9K | -$204.7K | |
| Cash From Investing | -- | -- | -- | -- | -- | |
| Cash From Financing | $612.2K | $1.1M | $932.7K | $355K | $160K | |
| Free Cash Flow | $12.5M | -$860.8K | -$1.1M | -$123.9K | -$204.7K | |
CBSC
Sector
Market Cap
$8.7M
$23.4M
Price % of 52-Week High
55.51%
48.49%
Dividend Yield
0%
0%
Shareholder Yield
-18.28%
-1.67%
1-Year Price Total Return
-11.64%
-23.18%
Beta (5-Year)
1.831
0.504
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$0.05
200-day SMA
Buy
Level
$0.04
Bollinger Bands (100)
Buy
Level
0.03 - 0.05
Chaikin Money Flow
Sell
Level
-1.7M
20-day SMA
Buy
Level
$0.04
Relative Strength Index (RSI14)
Buy
Level
68.83
ADX Line
Buy
Level
29.12
Williams %R
Neutral
Level
-30.2576
50-day SMA
Buy
Level
$0.04
MACD (12, 26)
Sell
Level
0.01
25-day Aroon Oscillator
Buy
Level
48
On Balance Volume
Sell
Level
-2.4M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-188.1896)
Sell
CA Score
(Annual)
Level (-53.8)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (114.2666)
--
Piotroski F Score
(Annual)
Level (--)
Buy
Quality Ratio Score
Level (4)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Cardiac Biotech Solutions, Inc. engages in the provision of products and services in the ambulatory non-invasive cardiac monitoring space. The firm's FDA and CE cleared EKG devices, interactive cloud-based acquisition software, and smartphone apps for both iOS and Android platforms, offer compliance for patients at risk of abnormal heart rhythms and information for physicians. The company was founded on June 22, 1987, and is headquartered in Las Vegas, NV.
Stock Forecast FAQ
In the current month, CBSC has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CBSC average analyst price target in the past 3 months is --.
-
Where Will Cardiac Biotech Solutions, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Cardiac Biotech Solutions, Inc. share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Cardiac Biotech Solutions, Inc.?
Analysts are divided on their view about Cardiac Biotech Solutions, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Cardiac Biotech Solutions, Inc. is a Sell and believe this share price will rise from its current level to --.
-
What Is Cardiac Biotech Solutions, Inc.'s Price Target?
The price target for Cardiac Biotech Solutions, Inc. over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is CBSC A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Cardiac Biotech Solutions, Inc. is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of CBSC?
You can purchase shares of Cardiac Biotech Solutions, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Cardiac Biotech Solutions, Inc. shares.
-
What Is The Cardiac Biotech Solutions, Inc. Share Price Today?
Cardiac Biotech Solutions, Inc. was last trading at $0.05 per share. This represents the most recent stock quote for Cardiac Biotech Solutions, Inc.. Yesterday, Cardiac Biotech Solutions, Inc. closed at $0.05 per share.
-
How To Buy Cardiac Biotech Solutions, Inc. Stock Online?
In order to purchase Cardiac Biotech Solutions, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get CBSC Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
CBSC
Sector
P/E ratio
--
23.40x
PEG ratio
--
-0.01x
P/B ratio
--
1.74x
Price / LTM sales
202.72x
1.48x
Growth Metrics
CBSC
Sector
Revenue growth
0.98%
3.36%
Earnings growth
--
9.35%
Revenue (5-year growth)
-19.43%
6.22%
Earnings forecast
--
-$0.19
Profitability
CBSC
Sector
Profitability FY 2024
--
$2.7M
Return on invested capital
--
-33.62%
Return on assets
-543.36%
-29.68%
Return on equity
--
-38.98%
Earnings Date
Last Earnings Date
Feb
8
Next Earnings Date
Feb
8
Estimated Next Earnings Date
May
10
Balance Sheet
CBSC
Sector
Total cash
$156K
$25M
Short term investments
--
$23.9M
Total assets
$167.4K
$72.5M
Long term debt
$143.3K
$2.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Lumentum The Best Laser Stock to Buy?
Though certainly less well-known than the huge tech businesses that…
Is Planet Fitness Stock Undervalued?
Planet Fitness (NYSE:PLNT) has had a difficult 12 months, retreating…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
53
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 30x
Alerts
Sell
40
BILL alert for Feb 7
Bill Holdings, Inc. [BILL] is up 37.11% over the past day.
Buy
75
PRLB alert for Feb 7
Proto Labs, Inc. [PRLB] is up 28.33% over the past day.
Sell
30
MSTR alert for Feb 7
Strategy, Inc. [MSTR] is up 26.08% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
